Search the Newsreel

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40

This article provides a quick overview of analyst ratings for Kura Oncology (KURA.US), noting a forecast price range of $23 to $40. It indicates that the company is currently receiving a 'Buy' rating from analysts, reflecting positive sentiment. The information is presented as a …

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

Hood River Capital (KRUS) reports 0% ownership of Kura Sushi USA common stock

Hood River Capital Management LLC has filed an amended Schedule 13G, reporting that it no longer holds any shares of Kura Sushi USA Inc. common stock, bringing its ownership down to 0%. The firm also indicates that it has no voting or dispositive power …

Kura Oncology (KURA) Stock Revenue Growth Clashes With Mounting Losses

Kura Sushi USA (KRUS): Stephens group discloses 1.10M-share, 9.9% ownership stake

Stephens Inc. and affiliated entities have filed an Amendment No. 8, disclosing a beneficial ownership stake of 1,102,847 shares, representing 9.9% of Kura Sushi USA, Inc.'s Class A common stock as of June 30, 2026. The filing indicates shared voting and dispositive power over …

Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside

Analysts have raised the average 12-month price target for Kura Oncology, Inc. (KURA) stock from $31.17 to $32, with forecasts ranging from $15 to $76 per share. This new target suggests a potential upside of approximately 222% from its August 12 closing price. The …

Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

Wedbush has increased its price target for Kura Oncology (NASDAQ:KURA) to $38.00 from $36.00, maintaining an "outperform" rating, which suggests a significant upside of 282.29% from its current stock price. This comes after Kura Oncology reported better-than-expected quarterly results, with a narrower loss per …

Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating

Wedbush has increased its price target for Kura Oncology (KURA) shares to $38 from $36, while maintaining an Outperform rating on the stock. This adjustment comes as the company continues its clinical development in precision medicine for cancer treatment. Kura Oncology is focused on …

Kura Sushi USA, Inc. (NASDAQ:KRUS) Receives Consensus Recommendation of "Hold" from Analysts

Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains

Kura Oncology reported strong Q2 2026 results, exceeding Wall Street expectations due to robust early sales of its new cancer drug KOMZIFTI. The company posted a smaller-than-expected loss and higher revenue, driven by KOMZIFTI capturing a majority share of new patient starts in the …

Kura Oncology (NASDAQ:KURA) Issues Earnings Results

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

Kura Oncology (KURA) reported a Q2 loss of $0.77 per share, beating the Zacks Consensus Estimate of a $0.89 loss, and revenues of $20.87 million, surpassing estimates by 23.61%. Despite underperforming the S&P 500 year-to-date, the stock holds a Zacks Rank #2 (Buy) due …

Kura Oncology Reports Second Quarter 2026 Financial Results

Kura Oncology announced its second quarter 2026 financial results, highlighting strong commercial performance for its drug KOMZIFTI® (ziftomenib), which generated $9.1 million in net product revenue and achieved a majority share of new patient starts in its class. The company also provided updates on …

Kura Oncology: Q2 Earnings Snapshot

Kura Oncology (KURA) grows revenue to $39.1M but widens net loss

Earnings Flash (KURA) Kura Oncology, Inc. Reports Q2 Revenue $20.9M, vs. FactSet Est of $20.2M

Kura Oncology, Inc. (KURA) reported Q2 revenue of $20.9 million, surpassing FactSet's estimated $20.2 million. This earnings flash indicates a positive revenue surprise for the biotechnology and medical research company. The report also mentions other recent financial news, including a widened Q2 diluted loss …

Kura Sushi USA (KRUS) investor Granahan reports 7.19% beneficial stake

Granahan Investment Management LLC has filed an amended Schedule 13G, disclosing a 7.19% beneficial ownership stake in Kura Sushi USA, Inc. (KRUS), totaling 801,969 shares of Class A common stock as of June 30, 2026. Granahan holds sole voting power over 610,809 shares and …

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

Kura Oncology announced the publication of a manuscript in Blood detailing the discovery and preclinical development of ziftomenib, a menin inhibitor approved by the FDA for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The publication highlights ziftomenib's differentiated binding profile, potent and selective …

Price to earnings forward of Kura Sushi USA, Inc. – NASDAQ:KRUS

Kura Oncology publishes preclinical data on ziftomenib in Blood By Investing.com

Kura Oncology has published preclinical data in Blood journal detailing the discovery and development of ziftomenib, a menin inhibitor approved by the FDA in 2025 for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The research highlights ziftomenib's efficacy across various leukemia …

Kura Oncology publishes study highlighting ziftomenib's unique action and potential in treating acute leukemias.

Kura Oncology announced the publication of a study in the journal Blood detailing the discovery and preclinical development of ziftomenib, an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The study highlights ziftomenib's potent and selective inhibition of the menin-KMT2A …

Dimensional Fund Advisors LP Increases Holdings in Kura Oncology, Inc. $KURA

Dimensional Fund Advisors LP significantly increased its stake in Kura Oncology, Inc. by 32.3% in the first quarter, now holding 1.43 million shares valued at $11.6 million. Other institutions also grew their positions, while an insider sold shares. Analysts maintain a "Moderate Buy" rating …

Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA

Hennion & Walsh Asset Management Inc. significantly increased its stake in Kura Oncology (NASDAQ:KURA) by 69.7% in Q2, bringing its total holdings to 568,845 shares valued at $6.24 million. Despite reporting a quarterly loss that beat estimates, revenue fell short, and an insider recently …

Dimensional Fund Advisors LP Raises Stake in Kura Sushi USA, Inc. $KRUS

Sei Investments Co. Has $3.08 Million Position in Kura Sushi USA, Inc. $KRUS

Kura Sushi USA (NASDAQ:KRUS) Downgraded to Sell Rating by Wall Street Zen

Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial data for Kura Oncology, Inc. (KURA), including its current stock price, historical performance, key statistics, earnings trends, and analyst ratings. It also offers an overview of the company's biopharmaceutical operations, focusing on its cancer treatment drug development.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six new employees. These grants were made on August 3, 2026, under the Company’s 2023 Inducement Option Plan, as amended, …

Six New Employees Receive Kura Oncology Options at $9.19

Kura Oncology (Nasdaq: KURA) has granted inducement awards of nonstatutory stock options to six new employees, totaling 104,500 shares. The options have an exercise price of $9.19 per share, matching the closing price on August 3, 2026, and will vest over four years. These …

Kura Oncology to Report Second Quarter Financial Results

Kura Oncology, Inc. announced it will report its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. The company …

Cancer drugmaker Kura Oncology schedules Aug. 12 webcast

Kura Oncology (Nasdaq: KURA) will report its second quarter 2026 financial results after the close of U.S. financial markets on Wednesday, August 12, 2026. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the …

How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing

This article analyzes Kura Oncology Inc. (KURA) for rotational strategy timing, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including long, breakout, and short positions, with entry points, targets, and stop losses derived from AI models. …